(RTTNews) - Eli Lilly and Company (LLY) announced updated results from the Phase 3 EMBER-3 study evaluating Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results